FDA accelerated path and Risto-cel 2026 catalysts, strong cash runway to 2029—read now. Click for more on BEAM.

Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency ...

Elon Musk said on Saturday that social media platform X ‍will open its new algorithm, including all code for organic and ...

Indonesia temporarily blocked Elon Musk's Grok chatbot on Saturday due to the risk of AI-generated ‍pornographic content, ...

CS-101 is Shanghai-based CorrectSequence's lead candidate, which it is developing for treating sickle-cell disease and ...

CS-101 is Shanghai-based CorrectSequence's lead candidate, which it is developing for treating sickle-cell disease and ...

GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared ...

The US Food and Drug Administration (FDA) has cleared GenEditBio Limited’s Investigational New Drug (IND) application to ...

Beam Therapeutics Inc. (NASDAQ: BEAM) is among the 12 Best Genomics Stocks to Invest In.

This post appeared first on Last Updated 57 seconds ago by Emily Standley-Allard If growing on social media feels like a ...

Instead of requiring personalized gene edits for each patient, the new approach could create a standardized method to use for many diseases. By Pam Belluck and Carl Zimmer Gene-editing therapies offer ...

Anne Angeletti runs a jewelry business with her daughter and granddaughter. At 101 years old, Anne Angeletti is still deeply passionate about her life's work. She is constantly on the move, bustling ...